Free tool
FAERS Monitor: Nucynta Er
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 200533 or its brand name (Nucynta Er, Tapentadol Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
33,575
Serious
30,074
90% of reports
Hospitalization
4,531
Death reported
20,764
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death11,645
- toxicity to various agents9,959
- overdose5,890
- drug abuse1,553
- drug dependence1,073
- drug ineffective1,039
- drug withdrawal syndrome neonatal944
- pain767
- nausea735
- accidental overdose721
- fatigue457
- headache418
- dizziness414
- somnolence409
- drug interaction404
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2008 | 2 |
| 2009 | 98 |
| 2010 | 155 |
| 2011 | 350 |
| 2012 | 418 |
| 2013 | 377 |
| 2014 | 364 |
| 2015 | 1,376 |
| 2016 | 1,060 |
| 2017 | 2,490 |
| 2018 | 21,688 |
| 2019 | 848 |
| 2020 | 729 |
| 2021 | 705 |
| 2022 | 593 |
| 2023 | 559 |
| 2024 | 706 |
| 2025 | 546 |
| 2026 | 510 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,020,584 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug withdrawal syndrome neonatalSignal | 944 | 42.6 | 39.9 | 35,883 |
| toxicity to various agentsSignal | 9,959 | 39.3 | 38.6 | 352,128 |
| overdoseSignal | 5,890 | 17.6 | 17.1 | 90,367 |
| accidental overdoseSignal | 721 | 12.6 | 11.7 | 7,533 |
| drug abuseSignal | 1,553 | 11.9 | 11.3 | 15,251 |
| deathSignal | 11,645 | 8.6 | 8.4 | 80,085 |
| drug dependenceSignal | 1,073 | 4.2 | 4.0 | 2,617 |
| drug interaction | 404 | 1.6 | 1.4 | 90 |
| somnolence | 409 | 1.3 | 1.2 | 24 |
| pain | 767 | 0.8 | 0.7 | 48 |
| nausea | 735 | 0.6 | 0.5 | 230 |
| dizziness | 414 | 0.5 | 0.5 | 188 |
| drug ineffective | 1,039 | 0.5 | 0.5 | 575 |
| headache | 418 | 0.4 | 0.4 | 350 |
| fatigue | 457 | 0.4 | 0.3 | 516 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.